Register to receive a free Global Urology Market Analysis, Size, and Trends Report synopsis and brochure. Benign Prostatic Hyperplasia (BPH) or enlarged prostates is a medical condition that affects millions of men, with over 750,000 cases diagnosed every year. Patients experience symptoms such as a weak urinating stream, nocturia, and much more. The challenge for
iData ResearchClinical Trial of a New BPH Treatment FDA Approved
Register to receive a free Urological Devices Market Report Suite for U.S. synopsis and brochure Scientists at ETH Zurich, a major Swiss science and technology university, have managed to 3D print a malleable stent small enough to be implanted into the urethrae of fetuses. According to the researchers, the device has features 40 times smaller than those
VANCOUVER, British Columbia-(BUSINESS WIRE)-According to the latest series of reports by iData Research, the United States urological device market is valued at over $2.9 billion, and is expected to reach $3.8 billion by 2025. The total market value includes multiple segments, such as urinary incontinence devices, stone management devices, benign prostate hyperplasia (BPH) treatment devices,
iData ResearchU.S. Urological Device Market to Reach $3.8 Billion by 2025, led by Boston Scientific and BARD – New Study by iData Research
Register to receive a free U.S. Market Report Suite for Urological Devices – MedSuite report synopsis and brochure. iData Research, a leading international medical market research and consulting firm, has released a new suite of reports which details the U.S. urological device market, including urinary incontinence statistics for 2019. A procedure volume analysis by iData Research
iData ResearchUrinary Incontinence Statistics 2019: Over 285,000 Procedures Performed Annually in the U.S.
Register to receive a free Urological Devices Market Report Suite for U.S. synopsis and brochure Dornier MedTech has recently launched their new OptiVision next-gen digital image processing technology at the 34th Annual EAU Congress in Barcelona. The OptiVision offers digital image processing that allows users to identify and consequently eliminate stones without the hassle of manual post-processing.
iData ResearchDornier MedTech Launches OptiVision for Stone Treatment and Endourology
Register to receive a free Urological Devices Market Report Suite for U.S. synopsis and brochure Urinary Incontinence Statistics There are well over 250,000 urinary incontinence procedures performed in the U.S. annually. The most common type of incontinence is stress urinary incontinence (SUI). This is a condition where urine is often lost during periods of intra-abdominal pressure, most
iData ResearchUrinary Incontinence Statistics Leaning Towards Patient Comfort
Register to receive a free Urological Devices Market Report Suite for U.S. synopsis and brochure MED-Fibers, Inc. announces the distribution of MED-Fibers, Inc. GrabHold™ Stone Basket with its Nitinol and tipless design allows for the positioning of the basket directly against the mucosal lining. This reduces bleeding and maintains a great and clear working field and reduced
iData ResearchMED-Fibers Announces New GrabHold™ Stone Basket
Register to receive a free Urological Devices Market Report Suite for U.S. synopsis and brochure Boston Scientific Corporation announced the global launch of the LithoVue Empower™ Retrieval Deployment Device, designed to be used with the LithoVue™ Single-Use Digital Flexible Ureteroscope and compatible nitinol retrieval basket to enable urologists to operate a ureteroscope and basket simultaneously when retrieving
Register to receive a free Urological Devices Market Report Suite for U.S. synopsis and brochure Boston Scientific announced that it has entered into a definitive agreement to acquire Augmenix, Inc., a privately-held company which has developed and commercialized the SpaceOAR® System, a therapy used to reduce common and debilitating side effects that men may experience after receiving
iData ResearchBoston Scientific Announces Agreement To Acquire Augmenix, Inc.
Register to receive a free Urological Devices Market Report Suite for U.S. synopsis and brochure Viveve Medical, Inc., a medical technology company focused on women’s intimate health, announced the initiation of LIBERATE-International, a multicenter, randomized, double-blinded, sham-controlled trial to evaluate the safety and efficacy of its proprietary, cryogen-cooled monopolar radiofrequency (CMRF) technology for the improvement of stress
iData ResearchViveve Initiates LIBERATE-International Trial for Improvement of Stress Urinary Incontinence